Europeiska unionen - engelska - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg - tablet, modified release - excipient ingredients: indigo carmine; hypromellose; hyprolose; allura red ac; magnesium stearate - idiopathic parkinsonism, where standard formulations containing levodopa/carbidopa have produced inadequate control. experience is limited with sinemet cr in patients who have not been treated with levodopa before.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: magnesium stearate; powdered cellulose; sodium sulfate; hyprolose; microcrystalline cellulose; trehalose dihydrate; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Irland - engelska - HPRA (Health Products Regulatory Authority)

fairmed healthcare gmbh - levodopa; carbidopa - tablet - 12.5/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Irland - engelska - HPRA (Health Products Regulatory Authority)

fairmed healthcare gmbh - carbidopa; levodopa - tablet - 10/100 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Irland - engelska - HPRA (Health Products Regulatory Authority)

fairmed healthcare gmbh - carbidopa; levodopa - tablet - 25/100 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Irland - engelska - HPRA (Health Products Regulatory Authority)

fairmed healthcare gmbh - carbidopa; levodopa - tablet - 25/250 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

USA - engelska - NLM (National Library of Medicine)

bluepoint laboratories - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 50 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions ). carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

USA - engelska - NLM (National Library of Medicine)

accord healthcare, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 50 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions ). carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.